Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 17, 2026Journal of Neurology Neurosurgery & Psychiatry

Comparative effectiveness of inebilizumab versus conventional immunotherapies in AQP4-IgG-positive NMOSD: a prospective cohort study with time-varying treatment effects

View Full Paper
Ask AI
Bookmark
Share

Authors

WHWenjuan HuangXZXintong ZhangZWZhouzhou Wang

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Huang et al. (2026) studied this question.

synapsesocial.com/papers/6aabb7275f706d05830e5f98https://doi.org/10.1136/jnnp-2026-339197
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-World Multicenter Cohort Study of Inebilizumab vs Low-Dose Rituximab in Neuromyelitis Optica Spectrum Disorders2026
  2. 2Inebilizumab in AQP4 ‐Seropositive NMOSD : One‐Year Follow‐Up From a Multicenter, Real‐World Study2026
  3. 3P.010 Safety and efficacy of inebilizumab in AQP4+ NMOSD participants with history of immunosuppression treatment prior to N-MOmentum study2024
  4. 4Comparative Evaluation of Rituximab Versus Approved Therapies in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Network Meta-analysis2026
  5. 5Safety and Effectiveness of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder: Interim Analysis of a Post-marketing Surveillance in Japan2026